Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 481 to 495 of 667 results for diabetes

  1. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  2. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  3. Pyelonephritis (acute): antimicrobial prescribing (NG111)

    This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

    Antimicrobial prescribing guideline
    Published
    31 October 2018
    View recommendations

    Sections for NG111

  4. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    2 June 2015
    View recommendations

    Sections for TA343

  5. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Withdrawn advice

  6. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Withdrawn advice

  7. Type 1 diabetes: insulin degludec (ESNM5)

    This evidence summary has been updated and replaced by NICE advice ESNM24.

    Withdrawn advice

  8. Diabetes: annual psychological assessment (children) (IND57)

    This indicator has been updated and replaced by NICE indicator 313 and NICE indicator 314.

    Withdrawn indicator

  9. Diabetes: thyroid disease screening (children) (IND56)

    This indicator has been updated and replaced by NICE indicator 312.

    Withdrawn indicator

  10. Diabetes: annual smoking status (children) (IND55)

    This indicator has been updated and replaced by NICE indicator 310 and NICE indicator 311.

    Withdrawn indicator

  11. Diabetes: annual foot examination (children) (IND54)

    This indicator has been updated and replaced by NICE indicator 308 and NICE indicator 309.

    Withdrawn indicator

  12. Diabetes: annual eye screening (children) (IND53)

    This indicator has been updated and replaced by NICE indicator 306 and NICE indicator 307.

    Withdrawn indicator

  13. Diabetes: annual urinary albumin (children) (IND52)

    This indicator has been updated and replaced by NICE indicator 304 and NICE indicator 305.

    Withdrawn indicator

  14. Diabetes: annual blood pressure (children) (IND51)

    This indicator has been updated and replaced by NICE indicator 302 and NICE indicator 303.

    Withdrawn indicator

  15. Diabetes: annual care processes (children) (IND48)

    This indicator has been updated and replaced by NICE indicator 296 and NICE indicator 297.

    Withdrawn indicator